|
|
Volumn 16, Issue 10, 1998, Pages 887-
|
|
Genentech is poised for an anti-cancer breakthrough
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIGEN;
ANTINEOPLASTIC AGENT;
GROWTH FACTOR RECEPTOR;
MONOCLONAL ANTIBODY;
PACLITAXEL;
RECEPTOR;
RITUXIMAB;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
BREAST CANCER;
CLINICAL TRIAL;
FOOD AND DRUG ADMINISTRATION;
GENE EXPRESSION;
HUMAN;
MALIGNANT NEOPLASTIC DISEASE;
NONHUMAN;
NOTE;
ONCOGENE NEU;
PRIORITY JOURNAL;
BREAST NEOPLASMS;
COMBINED MODALITY THERAPY;
DRUG INDUSTRY;
GENE THERAPY;
HUMANS;
IMMUNOTHERAPY;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 0031758182
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/nbt1098-887 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|